- Drugs
- Wednesday, 15 Apr 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
UnitedHealth Group Inc on Wednesday reported a better-than-expected quarterly profit due to strength in the pharmacy benefit business and maintained its forecast for the year, sending the company’s shares up nearly 3% before the bell.
UnitedHealth, the first health insurer to report results this earnings season, said its quarterly numbers reflect minimal impact from COVID-19 as the U.S. incidence of the fast-spreading respiratory illness worsened only late in the quarter.
The company said Andrew Witty, head of UnitedHealth’s pharmacy benefit unit, Optum, will take a leave of absence to help lead the World Health Organization’s new initiative for COVID-19 vaccine development.
UnitedHealth said it will continue to evaluate the impact of COVID-19 as the year progresses.
“UNH’s outlook demonstrates how well protected managed care sector earnings will be from the COVID-19 crisis in near term from the unprecedented restrictions on elective health care,” Stephens analyst Scott Fidel said.
The largest U.S. health insurer said it continues to expect adjusted net earnings of $16.25 to $16.55 per share for the year, the mid-point of which is above analysts’ estimate of $16.22, according to Refinitiv IBES data.
Health insurers including UnitedHealth, Cigna Corp and Anthem Inc have announced measures to reduce patient cost sharing on COVID-19 testing and care.
For the quarter ended March 31, earnings attributable to UnitedHealth shareholders fell 2.5% to $3.38 billion, or $3.52 per share, hurt by a 7.1% jump in operating expenses.
Related Industry Updates
Dry Eye Products Market 2031: Trends, Growth Drivers & Future Outlook
Nov 20, 2025
India will ship nearly 1,000 tonnes of paracetamol raw material to Europe
May 06, 2020
China Transmucosal Drug Delivery Systems Market Research With Size, Growth, Manufacturers, Segments And 2027 | 3M, Acrux, GW Pharmaceuticals
Feb 05, 2021
Sickle Cell Disease Treatment Market is expected to reach US$ 4,691.87 million by 2030
Nov 07, 2023
FDA Warns 15 Companies for Illegally Marketing Cannabidiol Containing Products
Dec 10, 2019
Applied BioMath, LLC Announces Collaboration with Northern Biologics
Apr 22, 2020
Alkermes Completes Avadel Deal, Expands Sleep Medicine Market Reach
Feb 13, 2026